Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

NCT03970837 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1764

Enrollment

INDUSTRY

Sponsor class

Stopped Only Asia cohort is early terminated.Limited efficacy demonstrated in the contRAst program does not support a suitable benefit/risk profile for otilimab as a potential treatment for RA. GSK has decided not to progress with regulatory submissions.

Conditions

Arthritis, Rheumatoid

Interventions

BIOLOGICAL: GSK3196165 (Otilimab)
DRUG: Tofacitinib
DRUG: Placebo

Sponsor

GlaxoSmithKline

Collaborators

[object Object]